Prime Securities Q1: consolidated PAT ₹2.0 Cr, down 81% YoY as Trigen Wealth costs bite
PAT -80.8% YoY · revenue -28.2% · margins compressing
₹26.53 Cr
-28.2% YoY
₹2.01 Cr
-80.8% YoY
5.97%
-16.4pp YoY
₹0.7
Prime Securities returned to consolidated profit in Q1 FY27 with PAT of ₹2.01 Cr (₹2.36 Cr before an associate loss of ₹0.35 Cr), recovering from a ₹13.22 Cr consolidated loss in Q4 FY26 — but on a year-on-year basis the print is sharply weaker: PAT fell ~81% from ₹10.48 Cr and total income dropped 28% to ₹33.68 Cr from ₹46.91 Cr a year ago. Stripping the ₹1.33 Cr current-quarter exceptional (an ECL top-up on the settled PRAL corporate-advisory claim), adjusted PAT is still down ~68% YoY, so the exceptional is not the story. The real driver is deliberate: the group is funding the ramp-up of its wealth vertical, Prime Trigen Wealth, which alone booked a PBT loss of ₹10.82 Cr (versus a ₹4.41 Cr loss in Q1 FY26), with employee expense up ₹9.38 Cr YoY. Consolidated net margin therefore compressed to ~6.0% from 22.3% a year earlier, the squeeze sitting almost entirely on the employee/build-out line rather than on the core advisory business.
Q1 FY-2027 vs prior quarters
The standalone accounts, which exclude the subsidiary drag, tell a much healthier story — standalone PAT of ₹9.06 Cr (EPS ₹2.67) on ₹17.08 Cr of income — a >3% divergence in trajectory from the consolidated view that readers should note is a structural funding effect, not a discrepancy. Management's own framing (press release) leans on "solid investment banking revenues" with a higher number and larger size of deals, consistent with the ₹1,220 Cr steel-infra acquisition Prime advised in June; it explicitly cautions that the advisory business "does not lend itself to quarterly comparisons." On the wealth build-out, management guides fixed costs of ~₹60 Cr in FY27 with trail-income revenue deferred ~a year by regulation, AUM/AUA already past ₹5,000 Cr (1,400+ clients, 105+ staff, 14 locations), income expected to begin Q2/Q3 FY27 and break-even in about five-to-six quarters. There is no prior formal guidance on record to score this against, and no brokerage consensus exists for a company of this size, so both the street and guidance angles are unknown. Cash plus investments stood at ~₹270 Cr.
The stock went into the print at ₹283, down 7.5% over the past month of trading.
What the summary numbers don't show
Exceptional item of ₹1.33 Cr — extra ECL allowance after PRAL settled its ₹27.95 Cr NCLT advisory claim for ₹17.50 Cr on Jun 4, 2026
W1
Trigen Wealth income onset from Q2/Q3 FY27 on the ₹5,000 Cr+ AUM/AUA base — does revenue begin to offset the ~₹60 Cr FY27 fixed cost
W2
Trigen PBT loss trajectory (₹10.82 Cr this quarter) against management's ~5-6 quarter break-even guidance
W3
Consolidated margin recovery: whether NPM rebuilds from ~6.0% as deal recognition (lumpy IB) and wealth income normalise
Source in ₹ Lakhs, converted to ₹ Cr. Consol PAT shown is line XI ₹2.01 Cr (incl associate share of loss ₹0.35 Cr, consistent with our comparison base); pre-associate PAT (line IX) is ₹2.36 Cr, which the press release headlines. Current quarter carries a net exceptional item of ₹1.33 Cr (additional ECL allowance after PRAL settled its ₹27.95 Cr NCLT advisory claim for ₹17.50 Cr on Jun 4, 2026); year-ago Q1FY26 had no exceptional, Q4FY26 had ₹11.78 Cr exceptional loss. Associate Ark Neo flagged with negative net worth (deferred-tax EOM). Consolidated absorbs Prime Trigen Wealth build-out losses; standalone does not.